This medicine is now known as Angiotensin 1-7.

On 20 June 2017, orphan designation (EU/3/17/1879) was granted by the European Commission to Envigo Pharma Consulting Limited, United Kingdom, for Asp-Arg-Val-Tyr-Ile-His-Pro (also known as TXA127) for the treatment of epidermolysis bullosa.

The sponsorship was transferred to Envigo CRS S.A., Spain, in April 2019.

Key facts

Active substance
Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7)
Disease / condition
Treatment of epidermolysis bullosa
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Envigo CRS S.A.
Carrer Argenters 6
Santa Perpetua de Mogoda 08130
Tel. +34 9371 37045

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating